INDEX

Abbreviated new drug applications (ANDAs), 43
Abciximab, 793
Abilify (aripiprazole), 1117
Absorption site, 548
ACAT inhibitors, 735
Accelerated approval, 78
Accelerator mass spectrometry, 249
ACE inhibitors, 708, 832
Acetaminophen, 656
Acetylcholine, 904
Acetylcholinesterase inhibitors (AChEI), 913
Activated protein C, 648
Active site protection in PEGylation, 474
Acute kidney injury (AKI), 1159, 1163
Acute phase response (APR), 1058
Acute Physiology and Chronic Health Evaluation II (APACHE II), 648, 650, 1163
ADME, 241
Adjuvants
- particulate vaccine, 537
- requirements of, 534
Aerodynamic diameter, 566
Age-related macular degeneration (AMD), 435
Agranulocytosis, 1113
Air pouch inflammation analgesic assay, 665
Alkylation agents, 973, 975
Alternative targets, 692
Alzheimer’s disease (AD), 780, 897, 929
Amebiasis, 1209
- pathogenesis of, 1211
Ames, Bruce, 1225
Amphipathicity, 306
Amyloid cascade, 912
Amyloid-β, 930

Amyotrophic lateral sclerosis (ALS or Lou Gehrig’s), 897–898
Analgesic drugs
- efficacy of, 118
- sites of action, 122
- use of, 115
Analogs, 552
Androgen antagonists, 980
Androstenedione, 1012
Angina, 710
Angiogenesis
- in arthritis, 1189
- inhibition of, 1065
Angiopoietins, 1189
Angiotensin-converting enzyme inhibitors (ACEi), 1168–1169
Angiotensinogen, 831
Animal models, 1193, 1213
Animal rule, 75
Animals for research, major providers of, 525
Anthracyclines, 978
Anthrax, 73, 76
Antianginal agents, 708
Antiarrhythmics under development, 716–717
Antibacterial activity, 308
Antibody
- affinity for, 1140
- humanization of, 108
- labeling of, 1141
Anticancer antibiotics, 978
Anticoagulants, 648
Antidepressants, 908
Antidiuretic hormone, 825
Anti-epidermal growth factor (EGF), 362

© 2012 John Wiley & Sons, Inc. Published 2012 by John Wiley & Sons, Inc.
Antifungal activity, 309, 622
Antifungal development, 622
Anti-inflammatory effects, 777
Anti-inflammatory therapy, 916
Antimetabolites, 975
Antimicrobial peptides (AMPs), 285
resistance to, 312
proline-containing native, 303
Antioxidant therapy, 916
Antiplatelet agents, 710
Antiprotozoan activity, 310
Antipsychotics
atypical, 1113
typical, 1111
Antipsychotics on prolactin elevation, effects of, 1121
Antisense neuropharmaceuticals, 900
Antisepsis, 1163
Antitumor activity, 310
Antitumor antibiotics, 979
Antiviral activity, 310
Antiviral agents
for HCV, 133
against hepatitis B, 130
against hepatitis C, 131
Apoptotic cascade, 913
Application user fees (PDUFA), 38
Aqueous aerosols, 580
generators, new, 582
Aromatase inhibitor, 979
Arrhythmias, 756
Aspartate, 906
Aspirin, 786, 802
as an antiplatelet agent, 589
pharmacokinetics of, 600
Assay optimization, 158
Assessment of tumor growth, 416
Asthma, 233
Atherosclerosis, 764
Atosiban, 1103
Atrial fibrillation, 781
Attachment inhibitors, 129
Autoimmune encephalomyelitis, 519
Avastin, 47, 371, 379
Bactericidal versus bacteriostatic effects, 620
“Bad bugs, no drugs” recommendations, 615
Bacteriophage, 638
Bangham, Alec, 539
Benchmark dose (BMD), 1224
Beta-blockers, 708
β-lactamases, 612
Bevacizumab, pharmacological formulation of, 50
Bexxar, 378
BDNF, 950
Bile acid reabsorption inhibitors (BARI), 736
Bioequivalence, 44
Biofilms, 617
Bioinformatics, 970
Biologic barriers for drug delivery, 768
Biologic target tractability, 31
Bio(muco)adhesion, 553
Biosafety laboratories, 85
Bioterrorism Act of 2002, 78
Biphosphates, 865
Bi-specific antibodies, 369
Bleeding, 802
Blood-brain barrier (BBB), 5, 6, 8, 10, 18, 618, 899
drug permeability through, 899
Blood compatibility, 51
Blood pressure, 1123
Bone degeneration, 780
Bosutinib, 1005
Brachytherapy, 419
Breast cancer, 1024, 1146
Brownian diffusion, 568
Buccal delivery, 552
Caco-2 cell, 549
Calpains inhibitors, 910
Cambridge Structural Database (CSD), 446
Camptothecins, 977
Carbon monoxide release compounds, 1163
Cardiovascular disease and metabolism, models of, 523
Cardiovascular disturbances, 1122
Cardiovascular toxicity of tyrosine kinase targeting drugs
used in oncology, 763
Carrageenan-induced rat paw edema (CPE), 665
Carrier molecules, 551
Cartilage
degradation, 849
repair reaction, 848
Caspase, 910
inhibitors, 1162
Catecholamines, 907
Cationic delivery systems, 431
CDC pathogen categories, 75
Celebrex, 657
Cell adhesion molecules, 92
Cell-based ELISA, 155
Cellular imaging analyses, 155
Cerebrovascular events, 1124
Changes in selected physiological parameters in pregnancy,
1094
Chemical central synapse, 902
Chemical moieties with undesirable properties list, 220
Chemical tractability, 28
Chemistry chelators for radiotheranostic applications, 414
Chemokines and chemokine receptors in arthritis, 1185
Chemokines, homeostatic, 1189
Chemotherapy, 963
Chimeric antibodies, 360
Chip-based assays, 234
Chlorpromazine, 1111
Cholestery transfer protein, 778
Cholestyramine, 773
Cholinergic deficits, 934
Cholinergic role in schizophrenia, 1131
Chondroitin sulfate (CS), 847, 855
Chronic inflammation and associated cancers, 1054
Chronic kidney disease, 1159
  therapeutic strategies for the treatment of, 1169
Clinical holds, 38
Clofibrate, 773
Clopidogrel, 589, 790
  response variability, mechanism of, 594
Coley, William, 1045
  Coley’s toxins, 1045
Colloidal carrier systems, 553
Colon cancer, 1149
Colon delivery, 552
Combinatorial drug discovery, 402
Commonly used animal models for human disease, 524
Comparative human microdose study, 245
Complementarity-determining region, 361
Computed tomography (CT), 413
Concentration-dependent drugs, 620
Condensation aerosols, 582
Conformationally selective MAB, 103
Congestive heart failure and myocarditis, 1123
COPD, 1233
Co-receptor binding, 129
Coronary artery disease (CAD), 785
Coronary heart disease (CHD), 723
Coxibs, 657
Crystal pathology, 447
Curcumin, 667
Cyclin-dependent kinase (CDK), 967
Cyclodextrins (CD), 549
Cyclooxygenase (COX-1), 590, 600, 656, 674
Cyclooxygenase-2 (COX-2), 114, 656
CYP1A2, 550
CYP2C19, 598, 818, 1067
CYP3A4, 549, 550, 597, 818, 827, 1094, 1167
CYP7A1, 726, 736
Cytotoxicity, 311

Definitive proof of structure, 445
Desalting, 183
Development state of PDE4 inhibitors, 1237
Dextran, 555
Diabetes mellitus, 803, 835, 1119
Diabetes, Type II, 525, 1118
Diabetic kidney disease, 1172
Diclofenac, 657
Diffractogram, 451
Digitalis, 707
“Disease-modifying” anti-rheumatic drugs (DMARDs), 881
Dopamine, 908
  receptors, ligands of, 908
Dose-effect relationship, 1222
Dose-response relationship, 1222
Doxycycline, 866
Doxylamine, 1104
“Drug-ability”, 157
Drug development process, 1101
Drug discovery pipeline, 12

Drug-eluting stents (DES), 801
Drug formulation, 984
Drug metabolites, 198
Drugs designed for use during pregnancy, 1103
Dry powder inhalers (DPI), 579
Dyspepsia, 814

Ebers papyrus, 3
Economic considerations, 31
Efflux pumps, 617
Ehrlich, Paul, 3
Electric charge, 568
Electrochemiluminescence (ECL) assay, 151
Electrospray ionization, 184
EMA Microdosing 2004 Paradigm, 248
Emergency use INDs, 36
Emulsions, 555
Enbrel (etanercept), 375
Encoding, 408
Endo, Akira, 773
Endochondral ossification, 851
Endocrine therapy, current status of, 1023
Endogenous inhibitors, 1194
Enhancing antimicrobial activity, 332
Enzyme inhibition, 551
Epigallocatechin 3-gallate, 667
Epipodophyllotoxins, 978
Erbilux (cetuximab), 379
Evaporation and condensation, 577
Excitotoxic cascade, 912
Excitotoxicity, 933

Fast track, 78
FDA approved therapeutic mAbs, 361, 363
FDA critical path initiative, 244, 274
FDA decisions on the application, 39
FDA exploratory IND guidance, 275
FDA guidelines on antibiotic approval, 614
FDAMA (Food and Drug Administration Modernization Act), 38
FDCA Food Additives Amendment, 468
FDCA (Food, Drug, and Cosmetics Act), 78
FDCA Section 505(b)(2) applications, 43
Fentanyl, 117
Fibrates, 723
Flavonoids, 863
Fleming, Alexander, 3, 611
Flowchart of inflammation, 658
Fluorescence-based assays, 150
Fluorescence polarization assays, 150
Folic acid antagonists, 975
Food chemicals codex, 468
Free radical scavengers, 1162
FRET assays, 150
Freund, Jules, 533, 537
  Freund’s complete adjuvant, 533, 884
Frog skin, 299
Functional mimetics, 945
Fusion inhibitors, 129, 130
γ-aminobutyric acid (GABA), 905
Gastroesophageal reflux disease (GERD), 814, 819
Gefitinib, 981
Gender difference, 748, 759
Gene delivery through nonviral polymeric vectors, 550
Generally regarded as safe (GRAS), 666
Ginger, 862
Gleevec, 466
Glucosamine sulfate (GS), 847, 855
Glutamate, 906
Glutamate hypothesis, 1131
Glyburide, 1104
Glycine, 906
Glycoprotein IIB/IIIA inhibitors, 747
Glycosylation, 194
Gonadotropin-releasing hormone agonists, 980
GPCRs, 746
G-proteins, 747
G-protein-coupled receptor (GPCR), 13, 661, 743, 748
G-protein-coupled receptor kinases (GRKs), 748
Guidelines for initiation of antiretroviral therapy in adults, 128
Halogens, 1141
Heart failure, 712, 759, 764
stages of, 713
Hemolytic activity, 310
Hemolytic potential, 51
Hepatitis B and C infections, 130
Hepatocyte growth factor (HGF), 1163
Herceptin, 365
Herpes virus, 132
Higher-organism-based assays, 212
High-performance liquid chromatography (HPLC), 181
High-throughput screening (HTS), 3, 12–14, 18, 147, 406, 967
assay types, 149
compatibility, 161
data analysis, 168
Histatins, 299
HMG-CoA reductase, 27
Hoffman, Felix, 599, 656
Hormonal agents, 978
Human Genome Project, 445, 708
Human hybridoma, 365
Human immunodeficiency virus (HIV), 127
protease inhibitors of, 456
Humanized antibodies, 360, 364
Human in vitro and in vivo studies, 1195
Human microdosing, 241–242, 268
pros and cons of, 246
Humira (adalimumab), 377
Huntington’s disease, 898
Hyaluronic acid (HA), 847, 855
Hydrogels, 555
Hydrophobicity, 304, 306
Hypertension, 762
Hypocholinergic cascade, 912
Ibuprofen, 657
IgA, 359
IgD, 359
IgE, 359
IgE-mediated processes, 1239
IgG, 359
IgM, 359
Imatinib, 980, 999
Immune stimulating complexes, 538
Immunocytokine drug conjugates, 366
Immunomodulation, 777
Improving drug delivery, 1215
Inactivating bacterial virulence factors, 617
Indomethacin, 656
Inertial impactors, 574
Inflammation, 932
definitions of, 655
initiators, as mediators of, 1054
in vitro assays of, 664
Inflammatory disease, 683
Influenza virus infections, 137
Inhibitors of maturation, 130
Institutional review boards (IRBs), 38
Integrase inhibitors, 130
Integrin structure, 92, 95
Interferon-A, 56
Interleukin-6, 885
Interleukin-15, 882
Interleukin-18, 884
Intestinal cholesterol absorption, 724
Investigational new drug applications (IND), 35, 77
In vitro cell lines, 989
Ion trap, 186
Ischemic stroke, 803
Jet nebulizers, 581
LD50, 1225
Linking groups, 407
Lipids
abnormalities, 1119
metabolism, 932
Lipinski’s Rule of Five, 404
Lipitor, 773
Liposomal delivery, 985
Liposomes, 539, 554
Lipoxygenase, 660
Lipoxygenase, 660
Low density lipoprotein cholesterol (LDL-C), 723, 726, 736, 773
Luciferase, 155
Luminescence-based assays, 151
Lumix assays, 151
Lung deposition, 569
Magnetic resonance imaging (MRI), 413
Malaria, 1208
Mass median aerodynamic diameter (MMAD), 574
Matzinger, Polly
“Danger Model”, 535
Maximum tolerated dose (MTD), 1224
Meadowsweet, 656
Merck, 773
Metabolic syndrome, 755, 764
Metastatic breast cancer, 1013
Metered-dose inhaler (MDI), 578
Methicillin nephrotoxicity, 612
Methicillin-resistant *S. aureus* (MRSA), 613
Methylsulfonylmethane (MSM), 864
Meyers, Adolph, 1111
Microcalorimetry, 152
Microdose, 241
Microencapsulation, 554
MicroRNA, 425
Microsomal triglyceride transfer protein (MTP), 736
Minocycline, 1162
Mitochondrial dysfunction, 1127
Mitogen-activated protein, 673
Mitogen-activated protein kinase family P38, 677
inhibitors, 1070
Mitogen-activated protein kinases (MAPKs), 674, 747, 758
Molecular imaging in cancer treatment, 413
Molecular size, 549
Molecules for the activation and resolution of inflammation, 659
Monoclonal antibody (mAb), 7, 359, 982
  current Phase III trials in U.S., 392–395
  under clinical development, 382–391
Mouse models, 992
Moxifloxacin, 619
Mpex Pharmaceuticals, 617
mTOR inhibitors, 982
Multidrug-resistant (MDR), 549
Multiple myeloma (MM), 1059
Murine hybridoma, 362
Myelodysplastic syndromes (MDS), 1059
Nanofl ow HPLC, 182
Nanoparticles, 553, 988
National Institute of Allergy and Infectious Disease (NIAID), 74
Natural products, 692, 964
drug discovery, 401
  libraries, 221
NCI 60 cancer cell lines, 990
Neovascularization, 851
Neurodegeneration in schizophrenia, 1124
Neuroimmunophilins, 951
Neuropathic pain, 673
Neuroprotection, 897
Neurotransmitter, life cycle of, 902
Neurotrophic proteins, 945
Neurotrophins, 943
Neutron diffraction, 450
New drug application (NDA), 35, 78
New molecular entities (NME), 25
Niacin/ribrates, 778
Nicotinic acids, 723, 773
Nilotinib, 1003
Nitric oxide synthase, 909
Nitrogen mustard agents, 974
Nitroglycerin, 709
Nitrosureas, 974
NMDA, 1126, 1129
Non-Hodgkin’s lymphoma (NHL), 414, 1145
Nonnucleoside analogs, 128
Nonsteroid anti-inflammatory drugs (NSAIDs), 114, 656, 674, 688
No-observed-adverse-effect level (NOAEL), 1124
Norepinephrine, 907
Novartis, 746
Nucleic acid based therapeutics, 8
Nucleoside analogs, 127
Nucleotide analogs, 128
Nutraceuticals in OA, 854
Obesity, 525
Off-target effects, 171, 428
Omega-3-polyunsaturated fatty acids, 667
Oncology
  marine sources, 965
  microbial sources, 966
Oncoytic virus, 60
Optimal absorption site, 552
Oral protein absorption, 547
Orbitrap, 186
Organ failure, 645
Orphan drug
  designations of, 78
  status of, 1106
Orthoclone OKT3, 360, 364, 371
Ospemifene, 1026
Osteoarthritis (OA), 847, 851, 859, 887
Ovarian cancer, 1146
Over-the-counter (OTC), 115
Oxidative cascade, 913
Oxidative degradation, 849
Oxidative stress, 931
Pacific yew tree, 965
Paclitaxel, 14, 5, 53
Pain, 687
  measures of, 119
Papillomavirus (HPV), 135
Paracelsus, 1221
Parasite life cycles and vectors, 1207
Parkinson’s disease (PD), 898
Particle
  interia, 566
  sizing of, 573
Pathway-specific screening, 211
PDUFA (Prescription Drug User Fee Act), 38
Pediatric assessments, 42
*Penicillium notatum*, 611
Peptic ulcer disease, 814
Peptide tagging, 409
Periferal arterial disease (PAD), 802
Permeability, 549
Permeabilization, 314
Permissible exposure level (PEL), 1222
Peroxisome proliferator-activated receptors (PPARs), 662, 779
Peyer's patch, 553
P-glycoprotein (P-GP), 549, 1094–1095
Phage display, 366
Pharmacognosy, 656
Pharmacokinetic behavior of selected anti-HIV drugs in pregnancy, 1105
Pharmacological formulation, 62
Phase 0 (zero) trials, 244
Phase 1 studies, 1102
pH changes in pregnancy, 1097
Phencyclidine (PCP), 1129
Phosphatidylinositol 3-kinase (PI3K), 748
Phosphodiester (PDE), 1126
Phosphorylated tau, 933
Photocleavable linkers, 408
Piscidins, 299
Placental physiology, 1094
species variation in, 1098
Planar scintigraphy, 416
Plant alkaloids, 976
Platelet-derived growth factor (PDGF), 749
Plate-reader-based assays, 214
Platinum agents, 975
Polarity and drug properties, 99
Polyethylene glycols (PEGs), 488, 550
PEG
alkylating, 469
branched-chain, 470
-chitosan, 500
conjugates, applications of, 483
conjugates, approved, 465
-glucagon, 467
islets, 502
properties of liquid, 503
properties of solid, 468
“stealth effect” of, 466
PEGnology, 463
PE Gylated liposomal doxorubicin, 56
PE Gylated proteins, lyophilization of, 482
PEGylation
in gene delivery, 475
of liposomes, 497
pharmacokinetic and pharmacodynamic effect of protein, 492
site-specific, 489
Poly(lactide-co-glycolide) (LCG), 538
Polymerase chain reaction (PCR), 364
Polymer-drug conjugates in clinical trials, 987
Polysaccharide intracellular adhesion (PIA), 633
Positron emission tomography (PET), 241, 242, 257, 413, 1138
assays, sensitivity of, 262
radiopharmaceuticals, 262
Postantibiotic effect (PAE), 621
Potentially cytotoxic groups, 220
Potential therapeutic index, 28
Powder diffraction file, 448
Poxvirus infections, 136
Prasugrel, 798
Preclinical studies demonstrating antitumor efficacy, 51
Priority review, 78
Prodrugs, 552, 988
Project Bioshield Act of 2004, 74, 79
Promiscuous drugs, 769
Proof of concept experiments, 216
Properties of safe and efficacious therapeutic agents, 691
Prostate cancer, 1025, 1148
Protease inhibitors, 128
Proteasome inhibitors, 53
Protectins, 661
Protein
binding in pregnancy, 1097
data bank, 674
kinases, 446
Protein kinase inhibitors, 981
involvement in heart disease, 744
Protein kinase C (PKC), 749
Proteolytic cleavage, 849
Proteomics in pharmaceutical analysis, 191
Proton pump inhibitors (PPIs), 598, 816, 819
Prostate cancer, 419
Prymidine analogs, 976
Pulmonary arterial hypertension, 752, 762
Purine analogs, 976
Pyridoxamine, 1172
QS21, 536
QTc interval prolongation, 1123
Quadrupole, 186
Quorum sensing inhibitors, 637
Rabbit hybridoma, 364–365
Radiation therapy (XRT), 413
Radioactive Drug Research Committee (RDRC), 247
Radiofrequency encoding, 410
Radioimmunotherapy (RIT), 1137, 1139
Ramon, Gaston, 533
Ranolazine, 709
Raptiva (efalizumab), 378
Rational drug design, 5
Remicade, 374
Removing toxicity to eukaryotic cells, 332
Renin-angiotensin system, 830
Renin inhibitors, 840
Reporter gene assays, 154
Requirement for registration of drugs in OA, 851
Research or investigator INDs, 36
Reservatrol, 667
Resistance, 1002
to classical antibodies, 285
Resolvins, 661
Restrictive barrier to antimicrobials, 632
Rheumatoid arthritis (RA), 7, 881, 883, 887, 1185
Rho-dependent serine-threonine kinases, 761
Rho-kinase, 764
Rhône-poulene, 1111
INDEX 1257

RII, 1143
  targeting, 1144
Risk evaluation and mitigation strategies (REMS), 41
RNA interface (RNAi), 8, 9
RNAi machinery, 426
Rodent collagen-induced arthritis (CIA), 665
Role of platelets in thrombotic events, 589
Rosa canina, 861
Ruboxistaurin, 1172
Safety
  and tolerability of PDE4 inhibitors, 1242
Sample purification, 181
SARMS, 1031
Schering-Plough, 725, 727
Schizophrenia, 1111, 1114
Screening
  design, 162
  INDs, 36
  quality control (QC), 164
Selected ABC transporters and substrates, 1096
Selecting targets for drug discovery, 32
Selective estrogen receptor modulator (SERM), 1011, 1019, 1026
Septic shock, 647
Sepsis, 645–646
  pathophysiology in, 645
Serotonin (5-hydroxytryptamine), 903
Short hairpin RNA (shRNA), 431
shRNAs
  design considerations, 433
  vector systems for expression of, 434
Single photon emission computed tomography (SPECT), 413
Single target screening, 211
Singleton versus mixture screening, 165
Small interfering ribonucleic acid (siRNAs), 207, 427
siRNA
  delivery, 430
  stability, 430
Small-molecule target tractability, 28
Smallpox act, 83
Sodium alginate (SA), 414
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 486
Solid-phase peptide synthesis, 402
Solubility, 984
Somatostatin antagonists, 1166
Spontaneously hypertensive rat (SHR), 523
Stability, 985
Standardized uptake value (SUV), 268
Statins, 709, 723, 726, 1171
  non-lipid-lowering effects of, 776
  withdrawal phenomenon of, 780
Stent thrombosis, 801
Stokes number (Stk), 566
Stroke, 759, 762, 898
Structure-based drug design, 456
Structure-modifying drugs, 852
Structure of an antibody, 360
Subchondral bone sclerosis, 851
Sudden cardiac death, 756
Sulfonamides, 611
Sunodexide, 1172
Surface-enhanced laser desorption, 190
Symptom-modifying drugs, 851
Synchrotron, 450
Synovium inflammation, 851
Systematic inflammatory response syndrome (SIRS), 645
Systemic hypertension, 751
Systems-based discovery (SBD), 14
Tamoxifen (TM), 1011, 1024
Target based discovery (TBD), 13–14
Target identification and validation, 148
Targeting the right epitopes, 1212
Target linkage to disease, 25
  by human clinical results, 26
  by human genetics, 26
Targets and therapeutic approaches for CNS disorders, 911
Tau protein cascade, 912
Taxanes, 977
Technique used for crystal growing, 447
TGNI1412, 11
Thalidomoid, 1062
Therapeutic agents for AKI, barriers to development of, 1160
Therapeutic application of antibodies, 91
Therapeutic investigational drugs, 135
Therapeutic proteins, greatest threat to, 548
Thermal motion and disorder, 448
Thrombin, 711
Thromboxane A2 (TXA2), 786
Ticlopidine, 789
Time constraints on FDA review, 39
Time-dependent drugs, 620
Time of flight (TOF) analyzer, 186
TNFR signaling
  TNFR-1, 1049
  TNFR-2, 1050
Toll-like receptor (TLR), 535, 662
Total respiratory tract deposition of inhaled particles, 566
Traditional synthetic drug discovery, 402
Tranquilizers, 908
Transgenic mice, 366
Transient ischemic attack (TIA), 803
Transports, 547, 549, 553
Traumatic brain injury, 898
Treatment INDs, 36
Trophoblastic tissue, 1099
Tumeric, 862
Tumor angiogenesis, 48
Tumor necrosis factor-α (TNF-α), 7, 881, 1045
  action, targets of, 1051
Twinning, 447
Tysabri (natalizumab), 380
Ultrasound, 413
Unspecific effects, 428
Vaccine Safety Act, 83
Vaccines
  emulsions in, 537
  immunological requirements of, 534
Vascular endothelial growth factor (VEGFs), 48, 709, 851, 1189
Vasodilators, 1163
Vasopressin, 714
Vasopressin receptor antagonists, 1166
  in clinical development, 1167
Vector selection, 433
Vinca alkaloids, 977
Vioxx (rofecoxib), 11, 114, 657
Vitamin B₁₂ conjugates for protein delivery, 556
Vitamin C, 859
vonWillebrand’s factor (vWF), 590, 711
Waksman, Salman, 612
Warfarin, 707
Weibel, 565
Willow, 656, 862
Wintergreen, 656
Xenogenic antibodies, 360
Yttrium-90, 114